Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer

This trial tests a combination of two experimental cancer drugs — HS-20093 (an antibody-drug conjugate targeting B7-H3) and HRS-5041 (a targeted hormone therapy) — in men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. **You may be eligible if...** - You are a man 18 or older - You have metastatic castration-resistant prostate cancer (mCRPC) — meaning it has spread and is no longer responding to hormone therapy - Your cancer progressed after at least one standard novel hormonal treatment (such as enzalutamide or abiraterone) - You are reasonably well and functional (ECOG score 0–1) with a life expectancy of at least 12 weeks **You may NOT be eligible if...** - You have previously received B7-H3 targeted therapy or AR PROTAC treatment - You have brain metastases - You have had other cancers - You have uncontrolled heart disease, active infections, or severe lung disease - You have significant unresolved side effects from prior treatment Talk to your doctor to see if this trial is right for you.